临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Clomipramine HCl
中文名称:盐酸氯米帕明
CAS号:17321-77-6
分子式: C19H23ClN2.HCl 分子量: 351.31
产品形式: Hydrochloride
研发状态: Enrolling by invitation
研发用途: Obsessive Compulsive Disorder
研究机构: Biohaven Pharmaceuticals Inc.
研发日期: March 30 2021
研发阶段: Phase 3
Clomipramine HCl(Anafranil) is a hydrochloride salt of clomipramine which is a serotonin transporter (SERT), norepinephrine transporter (NET) dopamine transporter (DAT) blocker with Ki of 0.14, 54 and 3 nM, respectively.
Varespladib (LY315920)
中文名称: 伐瑞拉迪
CAS号:172732-68-2
分子式: C21H20N2O5 分子量: 380.39
产品形式: free base
研发状态: Completed
研发用途: Healthy Volunteers
研究机构: Anthera Pharmaceuticals
研发日期: Jun-11
研发阶段: Phase 1
Varespladib (LY315920) is a potent and selective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor with IC50 of 7 nM. Phase 3.
Mepivacaine HCl
中文名称:盐酸甲哌卡因
CAS号:1722-62-9
分子式: C15H22N2O.HCl 分子量: 282.81
产品形式: HCl
研发状态: Not yet recruiting
研发用途: Knee Osteoarthritis; Hip Osteoarthritis
研究机构: Ottawa Hospital Research Institute
研发日期: Sep-22
研发阶段: Phase 4
Mepivacaine is a tertiary amine used as a local anesthetic.
Ilaprazole
中文名称:艾普拉唑
CAS号:172152-36-2
分子式: C19H18N4O2S 分子量: 366.44
产品形式: free base
研发状态: Not yet recruiting
研发用途: Pharmacokinetics
研究机构: Il-Yang Pharm. Co. Ltd.
研发日期: November 30 2024
研发阶段: Phase 1
Ilaprazole (IY-81149) is a new proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It inhibits H+/K+-ATPase with an IC50 of 6.0 μM.
Lu-135252
中文名称:达芦生坦
CAS号:171714-84-4
分子式: C22H22N2O6 分子量: 410.42
产品形式: free base
研发状态: Completed
研发用途: Coronary Artery Disease; Endothelial Dysfunction
研究机构: K.Lance Gould; Gilead Sciences; The University of Texas Health Science Center Houston
研发日期: Jun-09
研发阶段: Phase 2
Lu-135252 (Darusentan,HMR-4005) is a selective endothelin A receptor (ET-A receptor) antagonist indicated for the oral treatment of resistant hypertension.
Sodium Phenylbutyrate
中文名称:4-苯基丁酸钠盐
CAS号:1716-12-7
分子式: C10H11O2.Na 分子量: 187.19
产品形式: Sodium Salt
研发状态: Recruiting
研发用途: Corticobasal Syndrome (CBS)
研究机构: Technical University of Munich
研发日期: December 12 2023
研发阶段: Phase 2
Sodium phenylbutyrate (4-PBA, 4-Phenylbutyric acid, NaPB) is a salt of 4-phenylbutyrate (4-PBA) or 4-phenylbutyric acid.Sodium phenylbutyrate is a histone deacetylase inhibitor, used to treat urea cycle disorders.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
